Exon Skipping and Read Through Agents Panel

A brief introduction on the rationale behind mechanisms of endogenous dystrophin restoration, like exon skipping and read through agent therapies, followed by critical information and updates from the companies in this space. Moderated discussion included.

Barry Byrne, MD, PhD

Professor and Associate Chair

University of Florida, Department of Pediatrics

Jay Chauhan, PharmD

Medical Science Liaison

NS Pharma

Brett Crawford, PhD

Executive Director and Head of the Musculoskeletal Therapeutic Area

BioMarin Pharmaceutical Inc.

Ash Dugar, PhD

Senior Vice President, Medical Affairs

Dyne Therapeutics

Xiao Shelley Hu, PhD, MS


Wave Life Sciences

Matthew Klein, M.D., M.S., FACS

Chief Operating Officer

PTC Therapeutics

Nerissa Kreher, MD, MBA

Chief Medical Officer

Entrada Therapeutics

James McArthur, PhD

President and Chief Executive Officer


Mark Stahl, MD, PhD

Senior Medical Director, Clinical Development

Avidity Biosciences

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics

Related Resources

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.